PharmaZen boosts 2013 earnings on calcium pick up and new technology

PharmaZen boosts 2013 earnings on calcium pick up and new technology
By Suze Metherell April 4 (BusinessDesk) – Biotechnology company PharmaZen says full year pretax earnings rose 38 percent as it entered the retail market with its calcium supplement, StimuCal. PharmaZen posted a $739,114 profit in calendar 2013, up from $537,108 in 2012, the Dunedin-based company said in a statement. Sales lifted 4.7 percent to $7 million. Last year PharmaZen launched and patented StimuCal, the first time it had entered the retail market with a branded product. It developed the slow release calcium supplement after a link b...